Last reviewed · How we verify

NCT06915974

Comparison Between Interleukin 6 and Procalcitonin in Detecting Sepsis and Incidence of Mortality in Burn ICU Patients

Recruiting now NA Last updated 8 April 2025
What this trial tests

NA trial testing Interleukin 6 in Burns in 70 participants. Currently enrolling.

Timeline
10 January 2025
Primary endpoint
10 July 2025
10 July 2025

Quick facts

Lead sponsorAin Shams University
PhaseNA
StatusRecruiting now
Study typeINTERVENTIONAL
Allocationna
Designsingle group
Maskingnone
Primary purposeother
Enrollment70
Start date10 January 2025
Primary completion10 July 2025
Estimated completion10 July 2025
Sites1 location across Egypt

Drugs / interventions tested

Conditions studied

Sponsor

Ain Shams University

Who can join

Adults 25 to 60, any sex, with Burns or Sepsis. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

The investigators will compare the efficacy of Interleukin-6 (IL-6) as a better indicator than procalcitonin in burn patients with sepsis or septic shock regarding success of treatment and early ICU discharge.

Publications & conference data

No peer-reviewed publications indexed yet for this trial.

Verify or expand the search:

Other recruiting trials for Burns

Currently open trials in the same condition.

Other Ain Shams University trials

Trials by the same sponsor.

Verify against primary sources

Data sources for this page

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT06915974.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing